Brevan Howard Capital Management LP Makes New $258,000 Investment in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Brevan Howard Capital Management LP purchased a new stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 13,473 shares of the company’s stock, valued at approximately $258,000.

A number of other institutional investors have also recently modified their holdings of VRDN. R Squared Ltd purchased a new position in Viridian Therapeutics in the fourth quarter worth $26,000. Foresite Capital Management VI LLC acquired a new position in shares of Viridian Therapeutics during the 4th quarter worth $38,000. AlphaQuest LLC increased its holdings in shares of Viridian Therapeutics by 119.0% in the 4th quarter. AlphaQuest LLC now owns 2,795 shares of the company’s stock valued at $54,000 after purchasing an additional 1,519 shares in the last quarter. Summit Investment Advisors Inc. lifted its stake in shares of Viridian Therapeutics by 24.7% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company’s stock valued at $147,000 after purchasing an additional 1,516 shares during the period. Finally, Quantbot Technologies LP purchased a new stake in Viridian Therapeutics during the fourth quarter worth about $164,000.

Viridian Therapeutics Stock Down 1.9%

Shares of NASDAQ:VRDN opened at $12.54 on Monday. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $1.02 billion, a P/E ratio of -2.91 and a beta of 0.57. Viridian Therapeutics, Inc. has a 52-week low of $9.90 and a 52-week high of $27.20. The stock’s fifty day simple moving average is $13.71 and its 200-day simple moving average is $17.44.

Viridian Therapeutics (NASDAQ:VRDN) last announced its earnings results on Tuesday, May 6th. The company reported ($0.87) earnings per share for the quarter, beating the consensus estimate of ($0.95) by $0.08. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The firm had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.16 million. The company’s revenue was up .0% compared to the same quarter last year. As a group, equities research analysts forecast that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on VRDN. Needham & Company LLC dropped their target price on shares of Viridian Therapeutics from $38.00 to $36.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. The Goldman Sachs Group dropped their price objective on Viridian Therapeutics from $31.00 to $27.00 and set a “buy” rating for the company in a research note on Wednesday, May 7th. JMP Securities reduced their price objective on Viridian Therapeutics from $42.00 to $38.00 and set a “market outperform” rating for the company in a report on Wednesday, May 7th. HC Wainwright reiterated a “buy” rating and set a $34.00 target price on shares of Viridian Therapeutics in a research report on Wednesday, April 23rd. Finally, Royal Bank of Canada dropped their price target on Viridian Therapeutics from $46.00 to $45.00 and set an “outperform” rating for the company in a research report on Wednesday, May 7th. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, Viridian Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $36.70.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.